Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices

Sector: Healthcare

Phone: 646 650 1351

Website: volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

Stockprofiler May. 13 at 12:28 PM

$VNRX Great to see the bullish reversal. $3 incoming. @VolitionRx

0 · Reply

St0ckman691 May. 13 at 12:04 PM

$VNRX looks like the start of a reversal yesterday. With Q1 financials coming EOW the potential is there for a nice bounce.

0 · Reply

St0ckman691 May. 12 at 5:42 PM

$VNRX chart looking good here, huge upside for a bounce.

0 · Reply

Stockprofiler May. 12 at 5:32 PM

$VNRX HOD $2.35 Level 2 Shift #Bullish

0 · Reply

SmallCapGrowth May. 12 at 4:33 PM

$BCTX Phase 3 update: • 230+ patients enrolled in Bria-IMT trial • Strong site & patient demand • Interim results expected in 2026 Potential path toward approval in metastatic breast cancer if survival data is positive. NEWS: https://t.co/m0s9bNNz4n $ILLR $AIMN $VNRX

0 · Reply

byers07 May. 12 at 3:12 PM

$VNRX Watching here. Looks ready for a run. Do your DD

0 · Reply

UltimateTrader_22 May. 12 at 3:00 PM

$VNRX $2.29 +11.46% MARKET CAP 16.244 M VOLUME 118,678 -#SHORTSQUEEZE RSI(14) 34.13 @VolitionRx @Nasdaq

0 · Reply

AveraveJoeTrader May. 12 at 2:52 PM

$VNRX up 13 percent and starting to really ramp up here..

0 · Reply

Permabull67 May. 12 at 2:39 PM

$VNRX get it on the breakout boards

0 · Reply

AveraveJoeTrader May. 12 at 2:31 PM

$VNRX Could the short squeeze be just underway? Up 8 percent off bottom with volume picking up here..

0 · Reply

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

2026-05-07T06:07:48.000Z - 6 days ago

VolitionRx submits manuscript for Nu.Q Vet cancer test in cats

May 6, 2026, 8:17 AM EDT - 7 days ago

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

2026-04-29T14:40:22.000Z - 13 days ago

VolitionRx announces milestone in nucleosomes detection

Apr 29, 2026, 8:17 AM EDT - 14 days ago

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

2026-04-23T12:21:08.000Z - 20 days ago

VolitionRx’s compliance plan accepted by NYSE American

Apr 23, 2026, 8:12 AM EDT - 20 days ago

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

2026-04-20T12:05:06.000Z - 23 days ago

VolitionRx downgraded to Hold from Buy at D. Boral Capital

Apr 20, 2026, 7:30 AM EDT - 23 days ago

Volition Launches rNuQ™ Webshop Broadening Product Range

2026-04-02T16:11:44.000Z - 5 weeks ago

VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

Apr 1, 2026, 8:30 AM EDT - 6 weeks ago

VolitionRx Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:05 PM EDT - 6 weeks ago

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Mar 31, 2026, 8:16 AM EDT - 6 weeks ago

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Mar 30, 2026, 8:13 AM EDT - 6 weeks ago

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Mar 26, 2026, 8:17 AM EDT - 6 weeks ago

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

Mar 25, 2026, 4:12 PM EDT - 6 weeks ago

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

2026-03-25T13:04:07.000Z - 6 weeks ago

Why is VolitionRX Stock (VNRX) Up 24% Today?

Mar 25, 2026, 8:17 AM EDT - 7 weeks ago

Volition Announces Detection of Over 95% of Early-Stage Cancers

Mar 18, 2026, 8:17 AM EDT - 2 months ago

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

2026-03-06T13:18:03.000Z - 2 months ago

VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems

Mar 6, 2026, 8:10 AM EST - 2 months ago

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Feb 25, 2026, 8:10 AM EST - 2 months ago

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Feb 10, 2026, 8:07 AM EST - 3 months ago

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

2026-02-09T22:25:09.000Z - 3 months ago

VolitionRx receives non-compliance notice from NYSE American

2026-02-09T22:20:16.000Z - 3 months ago

VolitionRx files to sell 17.97M shares of common stock for holders

Feb 9, 2026, 5:20 PM EST - 3 months ago

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 4, 2026, 8:45 AM EST - 3 months ago

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

2026-01-30T13:55:53.000Z - 3 months ago

VolitionRx preparing reimbursement submission for Nu.Q cancer assays in France

Jan 30, 2026, 8:50 AM EST - 3 months ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Jan 27, 2026, 8:00 AM EST - 3 months ago

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

2026-01-20T13:38:55.000Z - 4 months ago

VolitionRx adds two laboratories providing its vet cancer test in U.S. and Asia

Jan 20, 2026, 8:25 AM EST - 4 months ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 16, 2026, 8:45 AM EST - 4 months ago

Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 8, 2026, 9:15 AM EST - 4 months ago

VolitionRx Secures $2.0 Million in Funding

2026-01-08T13:51:44.000Z - 4 months ago

VolitionRx announces clinical data for Nu.Q Vet cancer test in cats

Jan 8, 2026, 8:45 AM EST - 4 months ago

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Dec 17, 2025, 8:45 AM EST - 5 months ago

Volition Issues Business Review 2025

2025-12-11T14:15:38.000Z - 5 months ago

VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment

Dec 11, 2025, 9:00 AM EST - 5 months ago

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Dec 8, 2025, 9:00 AM EST - 5 months ago

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Dec 4, 2025, 9:00 AM EST - 5 months ago

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

2025-12-03T13:00:30.000Z - 5 months ago

VolitionRx downgraded to Hold from Buy at Maxim

Nov 25, 2025, 8:45 AM EST - 6 months ago

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

2025-11-17T16:25:14.000Z - 6 months ago

VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright

Nov 14, 2025, 8:30 AM EST - 6 months ago

VolitionRx Earnings Call Transcript: Q3 2025

2025-11-13T21:22:31.000Z - 6 months ago

VolitionRx reports Q3 revenue $600,000, consensus $715,590

Nov 13, 2025, 4:10 PM EST - 6 months ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 8:45 AM EST - 6 months ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Oct 17, 2025, 8:00 AM EDT - 7 months ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

2025-10-10T12:35:51.000Z - 7 months ago

VolitionRx announces pricing of $6M offering of common stock, warrants

Oct 10, 2025, 8:30 AM EDT - 7 months ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

2025-10-09T20:10:33.000Z - 7 months ago

VolitionRx announces offering of common stock and warrants, no amount given

Oct 9, 2025, 4:05 PM EDT - 7 months ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 8, 2025, 11:00 AM EDT - 7 months ago

VolitionRx Transcript: Status Update

Oct 2, 2025, 8:45 AM EDT - 7 months ago

Volition Sponsors Upcoming GenomeWeb Webinar

Sep 29, 2025, 9:30 AM EDT - 8 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Sep 9, 2025, 8:45 AM EDT - 8 months ago

Volition Signs First Human Out Licensing Deal

Aug 15, 2025, 8:30 AM EDT - 9 months ago

VolitionRx Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:10 PM EDT - 9 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 8, 2025, 8:30 AM EDT - 9 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 4, 2025, 4:01 PM EDT - 10 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Jul 16, 2025, 8:00 AM EDT - 10 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jun 12, 2025, 8:30 AM EDT - 11 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 4, 2025, 9:00 PM EDT - 1 year ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

May 19, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 16, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q1 2025

May 15, 2025, 5:37 PM EDT - 1 year ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 12, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 7, 2025, 8:30 AM EDT - 1 year ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025, 8:30 AM EDT - 1 year ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Mar 31, 2025, 4:30 PM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:05 PM EDT - 1 year ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Stockprofiler May. 13 at 12:28 PM

$VNRX Great to see the bullish reversal. $3 incoming. @VolitionRx

0 · Reply

St0ckman691 May. 13 at 12:04 PM

$VNRX looks like the start of a reversal yesterday. With Q1 financials coming EOW the potential is there for a nice bounce.

0 · Reply

St0ckman691 May. 12 at 5:42 PM

$VNRX chart looking good here, huge upside for a bounce.

0 · Reply

Stockprofiler May. 12 at 5:32 PM

$VNRX HOD $2.35 Level 2 Shift #Bullish

0 · Reply

SmallCapGrowth May. 12 at 4:33 PM

0 · Reply

byers07 May. 12 at 3:12 PM

$VNRX Watching here. Looks ready for a run. Do your DD

0 · Reply

UltimateTrader_22 May. 12 at 3:00 PM

$VNRX $2.29 +11.46% MARKET CAP 16.244 M VOLUME 118,678 -#SHORTSQUEEZE RSI(14) 34.13 @VolitionRx @Nasdaq

0 · Reply

AveraveJoeTrader May. 12 at 2:52 PM

$VNRX up 13 percent and starting to really ramp up here..

0 · Reply

Permabull67 May. 12 at 2:39 PM

$VNRX get it on the breakout boards

0 · Reply

AveraveJoeTrader May. 12 at 2:31 PM

$VNRX Could the short squeeze be just underway? Up 8 percent off bottom with volume picking up here..

0 · Reply

Samuelstark May. 12 at 2:28 PM

$VNRX

0 · Reply

i_like_bb_stock May. 12 at 2:02 PM

$VNRX "The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment" from most recent PR https://dilution.news/5dde988ac65cc51466be787ce16e0d84

0 · Reply

MulaBagz May. 12 at 1:59 PM

$VNRX back to $3+

0 · Reply

St0ckman691 May. 12 at 1:55 PM

$VNRX shorts going to be forced to cover here. Playing with fire 🔥🔥 https://nakedshortreport.com/company/VNRX

0 · Reply

AveraveJoeTrader May. 12 at 1:53 PM

$VNRX Bottom bounce underway as short squeeze looming..up 6 percent with conference call set for Friday..

0 · Reply

UltimateTrader_22 May. 12 at 1:53 PM

$VNRX #Shortsqueeze $2.275 +10.98% #Nasdaq #News

0 · Reply

Permabull67 May. 12 at 1:52 PM

$VNRX here we gooooo

0 · Reply

i_like_bb_stock May. 12 at 12:33 PM

$VNRX bottomed out here ready for an uptrend

0 · Reply

UltimateTrader_22 May. 12 at 12:31 PM

$VNRX The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment https://ir.volition.com/news-events/press-releases/detail/886/volitionrx-announces-submission-of-manuscript-for-nu-q-vet-cancer-test-in-cats @VolitionRx

0 · Reply

AveraveJoeTrader May. 12 at 12:29 PM

$VNRX $BTBT $SIDU All on watch..and here is why! 🎉👇🏻 https://x.com/autumnsdad1/status/2054155500590080393?s=61

0 · Reply

Stockprofiler May. 12 at 12:17 PM

$VNRX Evaluation of Circulating H3.1 Nucleosomes in the Plasma of Cats with Intermediate-large Cell Lymphoma https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6657098

0 · Reply

AveraveJoeTrader May. 11 at 7:50 PM

$VNRX Bounced of $2 as shorts fading..looking for bounce back here..

1 · Reply

Market Cap	16.58M
Revenue (ttm)	1.73M
Net Income (ttm)	-23.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,350.29%
Debt to Equity Ratio	-0.26

Volume	360,700
Avg Vol	722,594
Day's Range	N/A - N/A
Shares Out	8.09M
Stochastic %K	40%
Beta	1.03
Analysts	Strong Sell
Price Target	$16.83